![RENU-CA RESEARCH INSTITUTE [CENTER FOR DYSAUTONOMIA RESEARCH]](http://images.squarespace-cdn.com/content/v1/5a72077218b27dab4e3114f9/66e0a82c-a939-4933-b58a-ef513893d132/Unknown.jpg?format=1500w)
The RENU-CA Research Institute is a clinical research institute established by Dr. Ramesh Adiraju in 2005. The Institute was established to pursue novel endovascular techniques for the treatment of complex coronary and peripheral arterial disease and clinical research on autonomic nervous system imbalance.
Dr. Adiraju has extensive experience in coronary and endovascular interventions. Over the last 33 years, Dr. Adiraju has performed over 6000 coronary and valvular procedures and over 1500 peripheral vascular and endovascular procedures. Dr. Adiraju has particular interest in atherectomy to minimize the use of stents. His early (2005) complex coronary and peripheral atherectomy experience has been published. Dr. Adiraju also developed a novel technique for aortic valvuloplasty using peripheral cutting balloons as a simpler and less complicated alternative to transcatheter aortic valvuloplasty (TAVR) procedure.
Dr. Adiraju has performed several hundreds of complex high risk cardiovascular (CHIP) and peripheral vascular procedures for end-stage coronary artery disease patients and for limb salvage.
Dr. Adiraju has utilized Impella percutaneous heart pump in novel innovative protocols for supported revascularization of inoperable coronary artery disease and in the management of chronic congestive heart failure in advanced heart failure patients. He is the largest volume operator for Impella percutaneous heart pump in the Philadelphia area having performed more than 150 Impella procedures.
Dr. Adiraju also specializes in embolization procedures for life threatening bleeding and vascular aneurysms.
Dr. Adiraju also performs Abdominal Aortic Aneurism (AAA) repairs using a minimally invasive percutaneous approach without any cutting or surgical intervention.
Dr. Adiraju has also developed novel invasive techniques such as cutting balloon Aortic valvuloplasty, StepDown large bore access closure solution that have been published.
Dr. Adiraju, with extensive endovascular experience, has developed a novel atherectomy device, a guide wire and a prototype cutting balloon that have provisional patents.
Dr. Adiraju has also developed a novel approach to non-invasively assess coronary artery disease using a modality called Cardio Score-100 (CS-100) that can replace more expensive and laborious modalities such as CTA/CT-FFR (CT scan angiography) and nuclear stress testing. He has successfully implemented CS-100 testing to differentiate significant coronary artery disease from mild coronary artery disease and avoid unnecessary coronary angiography procedures. Over 3000 patients with coronary artery disease have been evaluated by this testing modality at RENU-CA Institute over the last 5 yrs. Dr. Adiraju’s CS-100 experience has been recently published.
At RENU-CA Institute Dr. Adiraju has identified a distinctive pattern of abnormality using CS-100 testing that can diagnose CMD - Coronary Micro-vascular Dysfunction. CMD has been identified as an abnormality that predisposes to cardiomyopathy and for chronic angina that has become a relentless problem in cardiology. Dr. Adiraju has identified a distinctive dysautonomia pattern and CS-100 pattern in CMP/CMD patients that responded well to autonomic neurohormonal modulation treatment successfully implemented at RENU-CA institute.
Through his research, Dr. Adiraju has developed testing protocols for diagnosis and identified dysautonomia as the etiology in several clinical conditions. Dr. Adiraju has identified dysautonomia as the underlying dysfunction for conditions such as Type II Diabetes, Metabolic Syndrome, systemic Inflammation with vasculopathy, cardiomyopathy, chronic congestive heart failure, postural orthostasis tachycardia syndrome (POTS), fibromyalgia, chronic fatigue syndrome, erythromelalgia, reflex sympathetic dystrophy (RSD), restless leg syndrome, syncopy/orthostatic hypotension, post traumatic stress disorder (PTSD), attention deficit disorder/hyperactive disorder (ADD/ADHD), central sleep apnea/sleep disorders, irritable bowel syndrome(IBS) and gastric motility disorders. Many of these conditions coexist due to the fact that dysautonomia is the underlying etiology. By addressing dysautonomia, Dr. Adiraju has developed a comprehensive and optimal treatment approach for many of these relentless conditions.
Dr. Adiraju has demonstrated autonomic dysfunction as the patho-physiological link between Diabetes, Cardio-vascular diseases and metabolic syndrome. Through dysautonomia research he has developed a comprehensive treatment program for diabetes and diabetic cardio-vascular complications called the Cardio-Diabetes program. Recently Dr.Adiraju has demonstrated a pattern of dysautonomia in long COVID syndrome patients. Based on the similarities of symptom complex experienced by Post COVID syndrome and classic dysautonomia syndrome, post COVID patients have been successfully treated and monitored by serial autonomic testing protocol.
Dr. Adiraju has developed definitive testing and treatment programs for LONG COVID SYNDROME based on dysautonomia and coronary microvascular dysfunction testing and treatment protocols that he developed at RENU-CA Institute. 118 LONG COVID patients have been successfully treated to date at RENU-CA institute. Link to RENU-CA LONG COVID protocols
Diabetic limb loss is a triple prong problem that involves peripheral venous insufficiency, arterial disease and neuropathy. Dysautonomia triggers arterial, venous capillary insufficiency, and peripheral neuropathy and hence is the underlying etiology for the triple prong problem. At the RENU-CA Research Institute, dysautonomia treatment protocols have been successfully implemented to address the triple prong problem for diabetic limb salvage. ADD has been increasingly diagnosed across all age groups, not only in children, and has serious life-long consequences in adulthood. Treatment of ADD/ADHD, particularly with increasing awareness of adult onset ADD, through autonomic regulation protocol reduces the need for psychoactive drugs and prevents serious long-term consequences such as Type ll Diabetes and cardiovascular illness. The Institute has become a leading resource for consultation and referral due to its stellar reputation among the medical and patient communities for its unique approaches in treatment of patients suffering from conditions related to dysautonomia. Over the last 13 years, patients have been referred to RENU-CA Research Institute from local institutions such as the University of Pennsylvania, Thomas Jefferson Center for Integrative Medicine, Princeton neurology and medical center, and patients who have been evaluated at out-of-state centers such as Mayo Clinic, Vanderbilt, to name a few, come to our Institute for second opinion and have received more definitive treatment for dysautonomia disorders such as EM and POTS. RENU-CA research is also posted as a referral center for EM patients on the Erythromylalgia foundation web site.